FDA Delivers 1st Drug Promo Rebuke Under Trump
The U.S. Food and Drug Administration's drug promotion office has issued its first discipline of the Trump administration, scolding Orexigen Therapeutics Inc. for omitting and obscuring the risks of weight loss...To view the full article, register now.
Already a subscriber? Click here to view full article